BRVE News
Archived Headlines
- US IPO Week Ahead: August IPO market opens with biotechs, a bank, and SpaceX earnings 07/31/26
- Cardiovascular diseases biotech Braveheart Bio sets terms for $300 million IPO 07/30/26
- US IPO Weekly Recap: Csquare and Standard Nuclear both underwhelm amid cautious market 07/17/26
- Cardiovascular diseases biotech Braveheart Bio files for a $100 million IPO 07/15/26
Renaissance Capital’s August IPO Market Update
Ten IPOs raised a combined $1.8 billion in August, joined by two direct listings. Activity slowed from July’s pace as the market entered its typical summer slowdown but was slightly above the month’s 10-year historical average (10 IPOs, $1.7B). Six...read more
IPO Winners & Losers: New Stocks Surge, Biotech Booms, and AI Rallies
Welcome back to Renaissance Capital’s IPO Winners and Losers, the weekly podcast breaking down the biggest stories shaping the IPO market. Click here to get the newsletter in your inbox every week.
...read moreUS IPO Weekly Recap: August kicks off with flurry of biotech IPOs
Six IPOs and five SPACs priced this week. Two IPOs and eight SPACs submitted filings. Cardiovascular disease biotech Braveheart Bio (BRVE) upsized and priced above the range, raising $383 million at a $1.6 billion market cap. Its lead candidate, BHB-1893, is ...read more
Cardiovascular diseases biotech Braveheart Bio prices upsized IPO at $18, above the range
Braveheart Bio, a Phase 3-ready biotech developing oral small molecules for cardiovascular diseases, raised $383 million by offering 21.3 million shares at $18, above the $15 to $17 range. It had originally planned to offer 18.8 million shares. Fidelity had...read more